Clinical Trials Browser

Phase 2 × Carcinoma in Situ × pembrolizumab × Clear all

NCT04387461 2024-09-25

CORE-001

Phase 2 Completed

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ